Enzalutamide, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV or Recurrent Endometrioid Endometrial Cancer
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- 51
Summary
- Conditions
- Recurrent Endometrial Endometrioid Adenocarcinoma
- Recurrent Uterine Corpus Carcinoma
- Stage III Uterine Corpus Cancer AJCC v7
- Stage IIIA Uterine Corpus Cancer AJCC v7
- Stage IIIB Uterine Corpus Cancer AJCC v7
- Stage IIIC Uterine Corpus Cancer AJCC v7
- Stage IV Uterine Corpus Cancer AJCC v7
- Stage IVA Uterine Corpus Cancer AJCC v7
- Stage IVB Uterine Corpus Cancer AJCC v7
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Only males
Description
PRIMARY OBJECTIVES: I. To determine the clinical activity of combination enzalutamide, carboplatin and paclitaxel represented as: Ia. Objective tumor response (complete response [CR] + partial response [PR]). Ib. The proportion of patients who survive progression-free for at least 6 months after ini...
PRIMARY OBJECTIVES: I. To determine the clinical activity of combination enzalutamide, carboplatin and paclitaxel represented as: Ia. Objective tumor response (complete response [CR] + partial response [PR]). Ib. The proportion of patients who survive progression-free for at least 6 months after initiating therapy. II. To quantify protein and phosphoprotein expression of androgen receptor (AR) and AR-response genes following enzalutamide treatment in match-paired pre and post treatment tumor biopsies. III. To determine the safety and feasibility of daily enzalutamide given in combination with carboplatin and paclitaxel in women with advanced stage or recurrent endometrial cancer. SECONDARY OBJECTIVES: I. Determine median response duration. II. Estimate progression free survival and overall survival. III. Evaluate for presence of pharmacokinetic interaction between enzalutamide and paclitaxel. EXPLORATORY OBJECTIVES: I. Correlate molecular results, including AR receptor expression and activation, to clinical endpoints. II. Identify potential agents to synergize with enzalutamide based on pathways activated after enzalutamide treatment. OUTLINE: Patients receive enzalutamide orally (PO) once daily (QD) alone on days 1-28. Patients then receive enzalutamide PO QD on days 1-21, paclitaxel intravenously (IV) over 3 hours on day 1, and carboplatin IV over 1 hour on day 1. Treatment repeats every 21 days for 6-9 cycles in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up every 3 months for up to 1 year.
Tracking Information
- NCT #
- NCT02684227
- Collaborators
- National Cancer Institute (NCI)
- Investigators
- Principal Investigator: Shannon N Westin M.D. Anderson Cancer Center
Get Well Soon